Growth Opportunities F. Forbion Purchases 41,639 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $5.97 per share, with a total value of $248,584.83. Following the acquisition, the insider now owns 2,059,459 shares in the company, valued at $12,294,970.23. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

enGene Price Performance

ENGN stock opened at $9.02 on Friday. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The company’s fifty day simple moving average is $6.71 and its 200 day simple moving average is $9.73. enGene Holdings Inc. has a 12-month low of $4.42 and a 12-month high of $43.00. The firm has a market cap of $398.38 million, a price-to-earnings ratio of -5.24 and a beta of -0.69.

enGene (NASDAQ:ENGN) last released its earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts expect that enGene Holdings Inc. will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Logos Global Management LP grew its holdings in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares during the period. Janus Henderson Group PLC acquired a new position in shares of enGene during the first quarter valued at about $17,095,000. SR One Capital Management LP bought a new position in shares of enGene during the 2nd quarter worth about $4,715,000. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the 1st quarter valued at about $2,039,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ENGN. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.